Cellromax Science Co., Ltd. Q3 operating profit KRW 0.8 billion, up 12.1% from a year earlier
AI summary · Not investment advice
Celomax Science sold KRW 4.9 billion in Q3 and earned KRW 0.8 billion from its main business, up 12.1% from a year earlier and down 15.8% from the prior quarter.
Operating profit · 3 months
KRW 825.9 million
Key facts
- Revenue (3 months)
- KRW 4.9 billion
- Net income (3 months)
- KRW 807.4 million
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 5.3 billion
- Revenue (year to date)
- KRW 14.7 billion
- Operating profit (prior-year 3 months)
- KRW 736.7 million
- Operating profit (year to date)
- KRW 2.2 billion
- Net income (prior-year 3 months)
- KRW 757.4 million
- Net income (year to date)
- KRW 2.8 billion
Commentary
AI commentary · Not investment advice
What happened
Cellomax Science reported its consolidated results for the 3rd quarter of 2026. Sales for the 3 months were KRW 4.93 billion. That is 7.5% lower than the same period a year earlier and 3.0% lower than the previous quarter.
In the company's terms
Operating profit (profit from the core business) for the 3 months was KRW 826 million. That is 12.1% higher than a year earlier and 15.8% lower than the previous quarter. Net income (the final profit after taxes and other costs) for the 3 months was KRW 807 million. That is 6.6% higher than a year earlier.
What changes for shareholders
For the year to date (Jan 1 to Sep 30), sales were KRW 14.73 billion. Operating profit was KRW 2.16 billion. Net income was KRW 2.80 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
C